GE Announces the Successful Completion of the Open Cycle of the Azito Phase IV Power Plant, Generating Approximately 8% of Ivory Coast Current Installed Electricity CapacityRead more Eco Atlantic Acquires Additional Participating Interest in Block 3B/4B Offshore South AfricaRead more Cellulant Recognised as a Leading Payment Platform Solutions Provider in Nigeria for its Tingg PlatformRead more Binance Signs Cristiano Ronaldo for Exclusive PartnershipRead more Human Rights Volunteer Roles to Return for FIFA World Cup QatarRead more White House ‘Social Media Summit’: No Facebook, No Twitter, No Transparency CopyRead more White House ‘Social Media Summit’: No Facebook, No Twitter, No TransparencyRead more White House ‘Social Media Summit’: No Facebook, No Twitter, No TransparencyRead more White House ‘Social Media Summit’: No Facebook, No Twitter, No TransparencyRead more White House ‘Social Media Summit’: No Facebook, No Twitter, No TransparencyRead more

WHO praises Oxford vaccine trial results cited in Lancet

show caption
Photo by James Gathany
Print Friendly and PDF

Jul 21, 2020 - 06:00 AM

GENEVA (AA) – The World Health Organization (WHO) on Monday welcomed developments in COVID-19 vaccine trials, singling out an Oxford University group while noting that the next move will have to be larger-scale real-world trials.

“It is good news. I mean, effectively, we have 23 COVID-19 candidate vaccines in clinical development. As of today, we had one candidate vaccine for which phase one clinical data was available,” said Dr. Mike Ryan, the executive director of WHO Health Emergencies Program.

He spoke at a WHO press webinar and commented on global vaccine developments following The Lancet medical journal, reporting that Oxford University’s coronavirus vaccine is safe and produces a positive immune reaction.

The early-stage human trials involved around 1,077 people with the results showing that the participants produced antibodies and white blood cells that can fight the virus.

Ryan said there are so far three vaccines in clinical development “in peer-reviewed journals” and another Pfizer product, for which the data is available on pre-publication.

“So, it is great to see the data coming through into peer-reviewed journals.

“We do welcome the study and congratulate our colleagues at the Oxford University’s Jenner Institute and the Oxford vaccine group, and our colleagues AstraZeneca for getting this data out there.”

Ryan also said the vaccine mentioned in The Lancet did generate a neutralizing antibody in participants.

“And in a very small number of participants that were given a booster dose, those responses were even greater,” he noted, and added that while it is a positive result, “there’s a long way to go.”

“These are phase one studies. We now need to move into larger-scale real-world trials.

“But it is good to see more data and more products moving into this very important phase of vaccine discovery, and we congratulate our colleagues for the progress they have made.” Ryan added.

The US-based Johns Hopkins University says there are more than 14.53 million confirmed cases of the novel coronavirus globally, with nearly 607,000 deaths from COVID-19 and almost 8.2 million recoveries. (Peter Kenny)


LMBCPOLITICS.COM uses both Facebook and Disqus comment systems to make it easier for you to contribute. We encourage all readers to share their views on our articles and blog posts. All comments should be relevant to the topic. By posting, you agree to our Privacy Policy. We are committed to maintaining a lively but civil forum for discussion, so we ask you to avoid personal attacks, name-calling, foul language or other inappropriate behavior. Please keep your comments relevant and respectful. By leaving the ‘Post to Facebook’ box selected – when using Facebook comment system – your comment will be published to your Facebook profile in addition to the space below. If you encounter a comment that is abusive, click the “X” in the upper right corner of the Facebook comment box to report spam or abuse. You can also email us.